A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
Public ClinicalTrials.gov record NCT06254950. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aim of this study is to learn if TAK-279 reduces bowel inflammation and symptoms compared to placebo. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate any problems. The participants will take capsules of either TAK-279 or placebo for up to 3 months (12 weeks). Then all the participants will receive TAK-279 for the rest of the treatment part of the study (1 year or 52 weeks). During the study, participants will visit their study clinic several times.
Study identification
- NCT ID
- NCT06254950
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 213 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 29, 2024 (Actual)
- Primary completion
- Jul 14, 2026 (Actual)
- Completion
- Aug 4, 2027 (Estimated)
- Last update posted
- Aug 17, 2026
2024 – 2027
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GastroIntestinal BioSciences | Los Angeles | California | 90067 | — |
| United Medical Doctors | Murrieta | California | 92563 | — |
| West Central Gastroenterology, LLP, d/b/a/ Gastro Florida | Clearwater | Florida | 33762 | — |
| Auzmer Research | Lakeland | Florida | 33813 | — |
| GI PROS, Inc. | Naples | Florida | 34102 | — |
| USF Health Morsani Center for Advanced Healthcare | Tampa | Florida | 33612 | — |
| Emory University Hospital, The Emory Clinic | Atlanta | Georgia | 30322 | — |
| Atlanta Center For Gastroenterology, P.C. | Decatur | Georgia | 30033 | — |
| University Of Louisville | Louisville | Kentucky | 40202 | — |
| Woodholme Gastroenterology Associates | Glen Burnie | Maryland | 21061 | — |
| Las Vegas Medical Research | Las Vegas | Nevada | 89113 | — |
| University Gastroenterology | Providence | Rhode Island | 02904 | — |
| Gastroenterology Associates, PA | Greenville | South Carolina | 29607 | — |
| Novel Research, LLC | Bellaire | Texas | 77401 | — |
| Tyler Research Institute, LLC | Tyler | Texas | 75701 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 125 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06254950, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06254950 live on ClinicalTrials.gov.